News

March 18, 2010
ImmunoGen, Inc. Announces Webcast of Presentation at the 2010 Barclays Capital Global Healthcare Conference

WALTHAM, Mass., Mar 18, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 2010 Barclays Capital Global Healthcare Conference at 3:45 pm ET on March 24, 2010. The Conference is being held at the Loews Miami Beach Hotel in Miami Beach, Florida. ImmunoGen's presentation will be webcast live and can be accessed through the "Investor Information" section of our website, www.immunogen.com. An archive of the webcast will be available at the same location until April 1, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's cancer-cell killing agents specifically to tumor targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.

SOURCE: ImmunoGen, Inc.

For Investors:
Carol Hausner, 781-895-0600
ImmunoGen, Inc.
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Adriana Jenkins, 617-744-1713

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?